Title: Developing an accessible dementia assessment tool: Leveraging a residual network, the trail making test, and demographic data
BackgroundThe global burden of Alzheimer's disease and related dementias is rapidly increasing, particularly in low- and middle-income countries where access to specialized healthcare is limited. Neuropsychological tests are essential diagnostic tools, but their administration requires trained professionals, creating screening barriers. Automated computational assessment presents a cost-effective solution for global dementia screening. ObjectiveTo develop and validate an artificial intelligence-based screening tool using the Trail Making Test (TMT), demographic information, completion times, and drawing analysis for enhanced dementia detection. MethodsWe developed: (1) non-image models using demographics and TMT completion times, (2) image-only models, and (3) fusion models. Models were trained and validated on data from the Framingham Heart Study (FHS) (N = 1252), the Long Life Family Study (LLFS) (N = 1613), and the combined cohort (N = 2865). ResultsOur models, integrating TMT drawings, demographics, and completion times, excelled in distinguishing dementia from normal cognition. In the LLFS cohort, we achieved an Area Under the Receiver Operating Characteristic Curve (AUC) of 98.62%, with sensitivity/specificity of 87.69%/98.26%. In the FHS cohort, we obtained an AUC of 96.51%, with sensitivity/specificity of 85.00%/96.75%. ConclusionsOur method demonstrated superior performance compared to traditional approaches using age and TMT completion time. Adding images captures subtler nuances from the TMT drawing that traditional methods miss. Integrating the TMT drawing into cognitive assessments enables effective dementia screening. Future studies could aim to expand data collection to include more diverse cohorts, particularly from less-resourced regions.  more » « less
Award ID(s):
2433726 2317079 1914792 2200052
PAR ID:
10618452
Author(s) / Creator(s):
; ; ; ; ; ; ; ; ; ;
Publisher / Repository:
Sage Journals
Date Published:
Journal Name:
Journal of Alzheimer’s Disease
ISSN:
1387-2877
Format(s):
Medium: X
Sponsoring Org:
National Science Foundation
More Like this
  1. null (Ed.)
    Aim:Although clinicians primarily diagnose dementia based on a combination of metrics such as medical history and formal neuropsychological tests, recent work using linguistic analysis of narrative speech to identify dementia has shown promising results. We aim to build upon research by Thomas JA & Burkardt HA et al. (J Alzheimers Dis. 2020;76:905–2) and Alhanai et al. (arXiv:1710.07551v1. 2020) on the Framingham Heart Study (FHS) Cognitive Aging Cohort by 1) demonstrating the predictive capability of linguistic analysis in differentiating cognitively normal from cognitively impaired participants and 2) comparing the performance of the original linguistic features with the performance of expanded features.Methods:Data were derived from a subset of the FHS Cognitive Aging Cohort. We analyzed a sub-selection of 98 participants, which provided 127 unique audio files and clinical observations (n = 127, female = 47%, cognitively impaired = 43%). We built on previous work which extracted original linguistic features from transcribed audio files by extracting expanded features. We used both feature sets to train logistic regression classifiers to distinguish cognitively normal from cognitively impaired participants and compared the predictive power of the original and expanded linguistic feature sets, and participants’ Mini-Mental State Examination (MMSE) scores.Results:Based on the area under the receiver-operator characteristic curve (AUC) of the models, both the original (AUC = 0.882) and expanded (AUC = 0.883) feature sets outperformed MMSE (AUC = 0.870) in classifying cognitively impaired and cognitively normal participants. Although the original and expanded feature sets had similar AUC, the expanded feature set showed better positive and negative predictive value [expanded: positive predictive value (PPV) = 0.738, negative predictive value (NPV) = 0.889; original: PPV = 0.701, NPV = 0.869].Conclusions:Linguistic analysis has been shown to be a potentially powerful tool for clinical use in classifying cognitive impairment. This study expands the work of several others, but further studies into the plausibility of speech analysis in clinical use are vital to ensure the validity of speech analysis for clinical classification of cognitive impairment. 
    more » « less
  2. Abstract INTRODUCTIONIdentification of individuals with mild cognitive impairment (MCI) who are at risk of developing Alzheimer's disease (AD) is crucial for early intervention and selection of clinical trials. METHODSWe applied natural language processing techniques along with machine learning methods to develop a method for automated prediction of progression to AD within 6 years using speech. The study design was evaluated on the neuropsychological test interviews ofn = 166 participants from the Framingham Heart Study, comprising 90 progressive MCI and 76 stable MCI cases. RESULTSOur best models, which used features generated from speech data, as well as age, sex, and education level, achieved an accuracy of 78.5% and a sensitivity of 81.1% to predict MCI‐to‐AD progression within 6 years. DISCUSSIONThe proposed method offers a fully automated procedure, providing an opportunity to develop an inexpensive, broadly accessible, and easy‐to‐administer screening tool for MCI‐to‐AD progression prediction, facilitating development of remote assessment. HighlightsVoice recordings from neuropsychological exams coupled with basic demographics can lead to strong predictive models of progression to dementia from mild cognitive impairment.The study leveraged AI methods for speech recognition and processed the resulting text using language models.The developed AI‐powered pipeline can lead to fully automated assessment that could enable remote and cost‐effective screening and prognosis for Alzehimer's disease. 
    more » « less
  3. PURPOSE: Disparities in lung cancer incidence exist in Black populations, and screening criteria underserve Black populations due to disparately elevated risk in the screening-eligible population. Prediction models that integrate clinical and imaging-based features to individualize lung cancer risk are a potential means to mitigate these disparities. METHODS: This multicenter (National Lung Screening Trial [NLST]) and catchment population–based (University of Illinois Health [UIH], urban and suburban Cook County) cross-sectional study used participants at risk of lung cancer with available lung computed tomography (CT) imaging and follow-up between the years 2015 and 2024. In all, 53,452 in NLST and 11,654 in UIH were included on the basis of age and tobacco use–based risk factors for lung cancer. Cohorts were used for training and testing of deep and machine learning models using clinical features alone or combined with CT image features (hybrid computer vision). RESULTSAn optimized seven-feature clinical model achieved receiver operating characteristic (ROC)-AUC values ranging from 0.64 to 0.67 in NLST and 0.60 to 0.65 in UIH cohorts across multiple years. Incorporation of imaging features to form a hybrid computer vision model significantly improved ROC-AUC values to 0.78-0.91 in NLST but deteriorated in UIH with ROC-AUC values of 0.68-0.80, attributable to Black participants where ROC-AUC values ranged from 0.63 to 0.72 across multiple years. Retraining the hybrid computer vision model by incorporating Black and other participants from the UIH cohort improved performance with ROC-AUC values of 0.70-0.87 in a held-out UIH test set. CONCLUSION: Hybrid computer vision predicted risk with improved accuracy compared with clinical risk models alone. However, potential biases in image training data reduced model generalizability in Black participants. Performance was improved upon retraining with a subset of the UIH cohort, suggesting that inclusive training and validation data sets can minimize racial disparities. Future studies incorporating vision models trained on representative data sets may demonstrate improved health equity upon clinical use. 
    more » « less
  4. OBJECTIVE:To determine biomarkers other than CA 125 that could be used in identifying early-stage ovarian cancer. DATA SOURCES:Ovid MEDLINE ALL, EMBASE, Web of Science Core Collection, ScienceDirect, Clinicaltrials.gov, and CAB Direct were searched for English-language studies between January 2008 and April 2023 for the concepts of high-grade serous ovarian cancer, testing, and prevention or early diagnosis. METHODS OF STUDY SELECTION:The 5,523 related articles were uploaded to Covidence. Screening by two independent reviewers of the article abstracts led to the identification of 245 peer-reviewed primary research articles for full-text review. Full-text review by those reviewers led to the identification of 131 peer-reviewed primary research articles used for this review. TABULATION, INTEGRATION, AND RESULTSOf 131 studies, only 55 reported sensitivity, specificity, or area under the curve (AUC), with 36 of the studies reporting at least one biomarker with a specificity of 80% or greater specificity or 0.9 or greater AUC. CONCLUSION:These findings suggest that although many types of biomarkers are being tested in ovarian cancer, most have similar or worse detection rates compared with CA 125 and have the same limitations of poor detection rates in early-stage disease. However, 27.5% of articles (36/131) reported biomarkers with better sensitivity and an AUC greater than 0.9 compared with CA 125 alone and deserve further exploration. 
    more » « less
  5. BackgroundRisk-based screening for lung cancer is currently being considered in several countries; however, the optimal approach to determine eligibility remains unclear. Ensemble machine learning could support the development of highly parsimonious prediction models that maintain the performance of more complex models while maximising simplicity and generalisability, supporting the widespread adoption of personalised screening. In this work, we aimed to develop and validate ensemble machine learning models to determine eligibility for risk-based lung cancer screening. Methods and findingsFor model development, we used data from 216,714 ever-smokers recruited between 2006 and 2010 to the UK Biobank prospective cohort and 26,616 high-risk ever-smokers recruited between 2002 and 2004 to the control arm of the US National Lung Screening (NLST) randomised controlled trial. The NLST trial randomised high-risk smokers from 33 US centres with at least a 30 pack-year smoking history and fewer than 15 quit-years to annual CT or chest radiography screening for lung cancer. We externally validated our models among 49,593 participants in the chest radiography arm and all 80,659 ever-smoking participants in the US Prostate, Lung, Colorectal and Ovarian (PLCO) Screening Trial. The PLCO trial, recruiting from 1993 to 2001, analysed the impact of chest radiography or no chest radiography for lung cancer screening. We primarily validated in the PLCO chest radiography arm such that we could benchmark against comparator models developed within the PLCO control arm. Models were developed to predict the risk of 2 outcomes within 5 years from baseline: diagnosis of lung cancer and death from lung cancer. We assessed model discrimination (area under the receiver operating curve, AUC), calibration (calibration curves and expected/observed ratio), overall performance (Brier scores), and net benefit with decision curve analysis.Models predicting lung cancer death (UCL-D) and incidence (UCL-I) using 3 variables—age, smoking duration, and pack-years—achieved or exceeded parity in discrimination, overall performance, and net benefit with comparators currently in use, despite requiring only one-quarter of the predictors. In external validation in the PLCO trial, UCL-D had an AUC of 0.803 (95% CI: 0.783, 0.824) and was well calibrated with an expected/observed (E/O) ratio of 1.05 (95% CI: 0.95, 1.19). UCL-I had an AUC of 0.787 (95% CI: 0.771, 0.802), an E/O ratio of 1.0 (95% CI: 0.92, 1.07). The sensitivity of UCL-D was 85.5% and UCL-I was 83.9%, at 5-year risk thresholds of 0.68% and 1.17%, respectively, 7.9% and 6.2% higher than the USPSTF-2021 criteria at the same specificity. The main limitation of this study is that the models have not been validated outside of UK and US cohorts. ConclusionsWe present parsimonious ensemble machine learning models to predict the risk of lung cancer in ever-smokers, demonstrating a novel approach that could simplify the implementation of risk-based lung cancer screening in multiple settings. 
    more » « less